Nostopharma

Executive Summary

Nostopharma is a San Diego-based preclinical biotechnology company founded in 2018, specializing in repurposing approved Hedgehog (Hh) pathway inhibitors for new therapeutic indications. Initially targeting neurodegenerative and inflammatory diseases, the company has pivoted its pipeline toward orthopedic trauma and oncology. Its lead program focuses on trauma-induced abnormal bone growth, a condition with no FDA-approved therapies, representing a significant unmet medical need. By leveraging the known safety profiles of existing Hh inhibitors, Nostopharma aims to accelerate development timelines and reduce regulatory risks. The company is privately held and operates with a lean, asset-light model, relying on partnerships and grant funding to advance its candidates through early-stage development. Despite its innovative approach, Nostopharma faces typical preclinical challenges, including securing financing, demonstrating in vivo efficacy, and navigating the competitive oncology and orthopedic landscapes. The company has not yet disclosed specific financials or development timelines, but its repurposing strategy offers a potentially faster path to clinical proof-of-concept. Key upcoming catalysts include the release of preclinical proof-of-concept data for its lead orthopedic trauma candidate, the filing of an IND application, and potential strategic partnerships to fund and co-develop its pipeline. The company’s success hinges on validating its repurposing approach in animal models and attracting partners with complementary expertise and resources.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data for lead orthopedic trauma candidate60% success
• Q2 2027IND application filing for lead candidate30% success
• Q1 2027Strategic partnership or licensing deal for oncology program40% success